Anthracycline-based chemotherapy is widely used in the management of breast cancer. Despite the lack of clinical evidence, obtaining prechemotherapy left ventricular ejection fraction (LVEF) by echocardiogram or multigated acquisition scan is a widely adopted practice throughout the world. We present here the results of a retrospective analysis of breast cancer patients who had LVEF measurements in anticipation of an anthracycline chemotherapy to determine whether predefined cardiac risk factors predicted for poor cardiac function. Retrospective data were analyzed from 482 female breast cancer patients in whom LVEF was measured before starting anthracyclinebased chemotherapy. Baseline demographics and multiple risk factors associated with congestive heart failure were collected. Twenty-six possible risk factors for CHF were defined, and the frequency of finding an abnormal LVEF as a function of total risk factors was assessed. Statistical tests include chi-squared and logistic regression analysis.
European Association of Cardiovascular Imaging (EACI) 19 state that baseline LVEF should be measured in all patients before starting doxorubicin. National Comprehensive Cancer Network (NCCN) guidelines while omitting the recommendation for evaluation of LVEF before anthracycline-based chemotherapy for breast cancer do, however, recommend LVEF evaluation with multigated acquisition scan (MUGA) or 2D-echocardiography (ECHO) particularly in older patients with lymphoma. 21 However, ECHO and MUGA do not appear to predict the development of anthracycline-related cardiac damage. A prospective study by Jensen et al 22 failed to show that evaluation of LVEF before therapy predicted subsequent cardiomyopathy for breast cancer patients who were treated with epirubicin. However, monitoring cardiac function after treatment for reduction of LVEF and development into CHF was of clinical benefit. Other analyses have also concluded that pretreatment evaluation of LVEF does not correlate with the development of subsequent cardiomyopathy. 22, 23 Not only is clinical trial data validating the need for prechemotherapy assessment of LVEF lacking, but also there is no evidence-based guideline recommending a routine post-chemotherapy LVEF assessment in an asymptomatic patient, who is at low risk of cardiac dysfunction. At our institution, we try to follow guideline recommendation to obtain LVEF to assess cardiac function on patients who are considered for anthracycline-based chemotherapy.
Whether a combination of patient's medical history and clinical examination are enough to determine that a patient has an adequate cardiac function to proceed with doxorubicin or any anthracycline is not clear. In this study, we hypothesized that in patients with no cardiovascular risk history, ECHO or MUGA does not provide additional decision-making information for anthracycline therapy over a patient's medical history and clinical exam. We also investigated whether this additional information obtained by LVEF measurement in asymptomatic patients altered the choice of preplanned chemotherapy with anthracycline to an alternative non-anthracycline-containing regimen.
| ME THODS
We reviewed medical records of adult female breast cancer patients (ages ≥18 years) who were treated at our institution between Jan- 
| RESULTS
The baseline patient characteristics are summarized in proceeded to a non-anthracycline-based therapy compared to 100%
in patients with RS >6.
| DISCUSSION
Chemotherapy regimens involving four cycles of dose-dense doxoru- 37, 38 The commonality of all these results lies in the consistent finding of very small if any benefit of LVEF assessments as a screening procedure. Our study is unique in that it further characterizes the risk factors for CHF. The difference between the past studies and our study lies in the inclusion of these recognized cardiac risk factors in the analysis. We used these defined risk factors to develop a risk score (RS) which was then cor- 
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